AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bionano Genomics, Inc. Director's Dealing 2018

Oct 3, 2018

35041_dirs_2018-10-03_888aafe5-abf6-4089-bdf6-7277ab9a2ab5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioNano Genomics, Inc (BNGO)
CIK: 0001411690
Period of Report: 2018-10-01

Reporting Person: Holmlin R. Erik (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-01	Stock Option (Right to Buy)	$7.77	A	256540	Acquired	2028-09-30	Common Stock (256540)	Direct

Footnotes

F1: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.